Literature DB >> 15044374

Low-protein diet during early life causes a reduction in the frequency of cells immunopositive for nestin and CD34 in both pancreatic ducts and islets in the rat.

E A Joanette1, B Reusens, E Arany, S Thyssen, R C Remacle, D J Hill.   

Abstract

Feeding a low-protein (LP) diet to pregnant and lactating rats impairs pancreatic islet mass and insulin release in the offspring, leading to glucose intolerance as adults. We hypothesized that an LP diet changes the number of pancreatic endocrine precursor cells or cells supporting endocrine cell neogenesis. Pregnant rats were given LP (8% protein) or a control (20% protein) diet from conception until postnatal d 21. Cells containing nestin, CD34, or c-Kit were quantified in pancreata of the offspring. Stellate cells immunoreactive for nestin were seen to be adjacent to ductal epithelium and were resident within the islets. These were proliferative and immunonegative for cytokeratin 20, fibronectin, tyrosine hydroxylase, pancreatic duodenal homeobox 1, Nk homeodomain transcription factor 6.1, or insulin, but expressed vimentin. Approximately 20% of islet nestin-positive cells also expressed the endothelial cell marker platelet endothelial cell adhesion molecule-1. Both ducts and islets also contained CD34- and c-Kit-positive cells with similar morphology to those expressing nestin. Offspring from rats fed the LP diet had significantly less nestin/CD34-positive cells and reduced expression of nestin mRNA. Within islets, there was an associated decrease in cell proliferation and in cells immunopositive for pancreatic duodenal homeobox 1. Nestin-positive cell number within islets correlated positively with the percent area of beta-cells. Supplementation of pregnant and lactating rats with taurine reversed the deficits in mean islet area and nestin-positive cells caused by the LP diet within the islets of the offspring. Nutritional programming of postnatal beta-cell mass may involve an altered abundance of cells expressing nestin and/or CD34, which may limit endocrine cell development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044374     DOI: 10.1210/en.2003-0796

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Nutritional programming of pancreatic β-cell plasticity.

Authors:  David J Hill
Journal:  World J Diabetes       Date:  2011-08-15

Review 2.  Development of the endocrine pancreas.

Authors:  David J Hill
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

3.  The CD34 surface antigen is restricted to glucagon-expressing cells in the early developing bovine pancreas.

Authors:  Claudia Merkwitz; Tiina Pessa-Morikawa; Paul Lochhead; Gessner Reinhard; Michiharu Sakurai; Antti Iivanainen; Albert M Ricken
Journal:  Histochem Cell Biol       Date:  2011-01-04       Impact factor: 4.304

Review 4.  Fetal programming and metabolic syndrome.

Authors:  Paolo Rinaudo; Erica Wang
Journal:  Annu Rev Physiol       Date:  2011-09-09       Impact factor: 19.318

5.  Islet-derived stem cells from adult rats participate in the repair of islet damage.

Authors:  JiaQing Gong; GuoHu Zhang; FuZhou Tian; Yonghua Wang
Journal:  J Mol Histol       Date:  2012-09-13       Impact factor: 2.611

6.  Offspring of Mice Exposed to a Low-Protein Diet in Utero Demonstrate Changes in mTOR Signaling in Pancreatic Islets of Langerhans, Associated with Altered Glucagon and Insulin Expression and a Lower β-Cell Mass.

Authors:  Renee King; Jessica L Hill; Bibek Saha; Yuzhen Tong; Brenda J Strutt; Mark A Russell; Noel G Morgan; Sarah J Richardson; David J Hill
Journal:  Nutrients       Date:  2019-03-12       Impact factor: 5.717

Review 7.  Pathological Mechanisms in Diabetes of the Exocrine Pancreas: What's Known and What's to Know.

Authors:  Qiong Wei; Liang Qi; Hao Lin; Dechen Liu; Xiangyun Zhu; Yu Dai; Richard T Waldron; Aurelia Lugea; Mark O Goodarzi; Stephen J Pandol; Ling Li
Journal:  Front Physiol       Date:  2020-10-28       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.